These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33967759)

  • 41. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
    Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
    [TBL] [Abstract][Full Text] [Related]  

  • 43.
    Han SY; Zhao W; Han HB; Sun H; Xue D; Jiao YN; He XR; Jiang ST; Li PP
    Oncotarget; 2017 Aug; 8(34):56893-56905. PubMed ID: 28915640
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.
    Zhou J; Hu Q; Zhang X; Zheng J; Xie B; Xu Z; Zhang W
    Oncol Rep; 2018 Apr; 39(4):1783-1792. PubMed ID: 29393480
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib.
    Xu W; Wei Y; Wu S; Wang Y; Wang Z; Sun Y; Cheng SY; Wu J
    Cell Biosci; 2015; 5():7. PubMed ID: 25973173
    [TBL] [Abstract][Full Text] [Related]  

  • 47. IL-22 Confers EGFR-TKI Resistance in NSCLC via the AKT and ERK Signaling Pathways.
    Wang X; Xu J; Chen J; Jin S; Yao J; Yu T; Wang W; Guo R
    Front Oncol; 2019; 9():1167. PubMed ID: 31750252
    [No Abstract]   [Full Text] [Related]  

  • 48. Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib.
    Liu X; Carlisle DL; Swick MC; Gaither-Davis A; Grandis JR; Siegfried JM
    Exp Cell Res; 2007 Apr; 313(7):1361-72. PubMed ID: 17349623
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization.
    Yeung YT; Yin S; Lu B; Fan S; Yang R; Bai R; Zhang C; Bode AM; Liu K; Dong Z
    EBioMedicine; 2018 Feb; 28():51-61. PubMed ID: 29398601
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
    Li XY; Wu JZ; Cao HX; Ma R; Wu JQ; Zhong YJ; Feng JF
    Oncol Rep; 2013 May; 29(5):1975-82. PubMed ID: 23440266
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synergistic interaction between MEK inhibitor and gefitinib in EGFR-TKI-resistant human lung cancer cells.
    Li S; Chen S; Jiang Y; Liu J; Yang X; Quan S
    Oncol Lett; 2015 Oct; 10(4):2652-2656. PubMed ID: 26622906
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
    Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
    Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
    Morgillo F; Kim WY; Kim ES; Ciardiello F; Hong WK; Lee HY
    Clin Cancer Res; 2007 May; 13(9):2795-803. PubMed ID: 17473213
    [TBL] [Abstract][Full Text] [Related]  

  • 54. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
    Ge P; Cao L; Chen X; Jing R; Yue W
    BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Involvement of GLUT1-mediated glucose transport and metabolism in gefitinib resistance of non-small-cell lung cancer cells.
    Suzuki S; Okada M; Takeda H; Kuramoto K; Sanomachi T; Togashi K; Seino S; Yamamoto M; Yoshioka T; Kitanaka C
    Oncotarget; 2018 Aug; 9(66):32667-32679. PubMed ID: 30220973
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.
    Choi YJ; Rho JK; Jeon BS; Choi SJ; Park SC; Lee SS; Kim HR; Kim CH; Lee JC
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):381-8. PubMed ID: 19921194
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.
    Yun M; Kim EO; Lee D; Kim JH; Kim J; Lee H; Lee J; Kim SH
    Cell Physiol Biochem; 2014; 34(3):865-72. PubMed ID: 25199820
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant progression of lung cancer cells and increased the sensitivity to chemotherapy.
    Huo H; Feng Y; Tang Q
    Cancer Chemother Pharmacol; 2024 May; 93(5):397-410. PubMed ID: 38172304
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
    Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.